Collegium Pharmaceutical (COLL) Expected to Announce Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Collegium Pharmaceutical to post earnings of $1.68 per share and revenue of $199.6250 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the firm posted $1.49 EPS. Collegium Pharmaceutical’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.23 during trading hours on Tuesday, hitting $35.81. The company’s stock had a trading volume of 8,502 shares, compared to its average volume of 466,795. The company has a market cap of $1.16 billion, a PE ratio of 17.55 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The business has a 50 day moving average price of $34.87 and a two-hundred day moving average price of $37.40. Collegium Pharmaceutical has a 12-month low of $29.70 and a 12-month high of $50.79.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of COLL. Janus Henderson Group PLC lifted its position in shares of Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares during the period. Millennium Management LLC increased its holdings in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares during the period. Two Sigma Investments LP raised its stake in Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after buying an additional 242,310 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in Collegium Pharmaceutical by 237.9% in the third quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after buying an additional 225,679 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in Collegium Pharmaceutical by 854.2% during the third quarter. Voloridge Investment Management LLC now owns 249,473 shares of the specialty pharmaceutical company’s stock worth $8,729,000 after buying an additional 223,329 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.